IDEXX Laboratories Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
IDEXX Laboratories şirketinin toplam hissedar öz sermayesi $1.6B ve toplam borcu $873.9M olup, bu da borç-öz sermaye oranını 54% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.4B ve $1.7B dir. IDEXX Laboratories 'in FAVÖK'ü $1.2B faiz karşılama oranı 62.3 dur. Şirketin $308.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
54.0%
Borç/özkaynak oranı
US$873.90m
Borç
| Faiz karşılama oranı | 62.3x |
| Nakit | US$308.64m |
| Eşitlik | US$1.62b |
| Toplam yükümlülükler | US$1.73b |
| Toplam varlıklar | US$3.35b |
Son finansal sağlık güncellemeleri
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Recent updates
Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: IDXX 'nin kısa vadeli varlıkları ( $1.4B ) kısa vadeli yükümlülüklerini ( $1.0B ) aşıyor.
Uzun Vadeli Yükümlülükler: IDXX şirketinin kısa vadeli varlıkları ( $1.4B ) uzun vadeli yükümlülüklerini ( $723.5M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: IDXX 'nin net borç/öz sermaye oranı ( 34.9% ) tatmin edici olarak değerlendirilmektedir.
Borcun Azaltılması: IDXX 'nin borç/öz sermaye oranı son 5 yılda 456.8% seviyesinden 54% seviyesine düştü.
Borç Kapsamı: IDXX 'nin borcu işletme nakit akışı ( 104.9% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: IDXX 'in borcuna ilişkin faiz ödemeleri EBIT ( 62.3 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.